Mild Cognitive Impairment Market: Analysis of Epidemiology, Pipeline Products, and Key Companies Working, DelveInsight | Alzheon Inc., AriBio Co., Ltd., Eli Lilly, Novo Nordisk, AgeneBio, Inc., Anavex Life Sciences Corp., TauRx Therapeutics, Araclon Biote

Mild Cognitive Impairment emerging therapies such as LEQEMBI (lecanemab), KISUNLA (Donanemab), and others are expected to boost the Mild Cognitive Impairment Market in the upcoming years.

DelveInsight has launched a new report on "Mild Cognitive Impairment - Market Insights, Epidemiology, and Market Forecast-2034" that delivers an in-depth understanding of the Mild Cognitive Impairment, historical and forecasted epidemiology as well as the Mild Cognitive Impairment market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Download sample pages to know more about mild cognitive impairment market @ https://www.delveinsight.com/report-store/mild-cognitive-impairment-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Recent advancements in the Mild Cognitive Impairment Market:
In January 2023, the U.S. Food and Drug Administration (FDA) granted accelerated approval for Leqembi, developed by Eisai R&D Management Co., Ltd., for the treatment of Alzheimer's disease. This approval was based on Leqembi's ability to reduce amyloid beta plaques, a hallmark of Alzheimer's pathology. The treatment is indicated for patients in the early stages of Alzheimer's, encompassing those with mild cognitive impairment or mild dementia.
Eli Lilly's Kisunla received approval from Japan's Ministry of Health, Labor and Welfare for use in adults with early symptomatic Alzheimer's disease. Kisunla offers an option for those in the early stages of Alzheimer's, with patients potentially discontinuing therapy if their amyloid levels fall below a certain threshold.

Some of the key facts of the Mild Cognitive Impairment Market Report:

In 2023, the Mild Cognitive Impairment (MCI) market across the seven major markets (7MM) was valued at approximately USD 2,836 million, with expectations for continued growth through 2034. The United States held the largest market share within the 7MM, reaching around USD 1,467 million in 2023, a figure projected to rise further by 2034.
According to DelveInsight's assessment, the estimated number of diagnosed Parkinson's disease cases in the U.S. reached approximately 1.211 million in 2023.
Among European nations, Germany recorded the highest number of diagnosed Alzheimer's disease cases, with around 1.491 million in 2023, followed by France, which had approximately 1.17 million cases. In contrast, the UK had the lowest diagnosed prevalence, with 620,000 cases.
Germany recorded the highest diagnosed prevalence of MCI in Parkinson's disease among the EU4 and the UK, with nearly 223,000 cases in 2023, a number anticipated to increase by 2034. In the same year, the United States had the highest number of Alzheimer's disease cases within the 7MM, affecting around 6.98 million people, with DelveInsight forecasting further growth in prevalence by 2034.
Among the 7MM, the U.S. accounted for the highest percentage of MCI cases at 42%, followed by Japan (27%), Germany (10%), and France (7%). Experts predict a rise in overall diagnosed cases in the coming years. The current MCI market includes approved therapies such as LEQEMBI (lecanemab) and off-label treatments like cholinesterase inhibitors and memantine, contributing to a market size of USD 222 million in 2023. The market is expected to expand with the introduction of emerging therapies between 2024 and 2034.
In July 2024, the U.S. FDA approved KISUNLA (donanemab-azbt, 350 mg/20 mL), developed by Eli Lilly, for treating early symptomatic Alzheimer's disease, including Mild Cognitive Impairment and mild dementia with confirmed amyloid pathology.
Japan's MCI market was valued at approximately USD 670 million in 2023, representing 24% of the total 7MM market, with projections indicating further growth by 2034.
Key Mild Cognitive Impairment companies such as Alzheon Inc., AriBio Co., Ltd., Eli Lilly, Novo Nordisk, AgeneBio, Inc., Anavex Life Sciences Corp., TauRx Therapeutics, Araclon Biotech S.L., AC Immune SA, Johnson & Johnson, and others are evaluating new drugs for Mild Cognitive Impairment to improve the treatment landscape.
Promising Mild Cognitive Impairment pipeline therapies in various stages of development include LEQEMBI (lecanemab), KISUNLA (Donanemab), and others.
Key benefits of the Mild Cognitive Impairment market report:
Mild Cognitive Impairment market report covers a descriptive overview and comprehensive insight of the Mild Cognitive Impairment Epidemiology and Mild Cognitive Impairment market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
The Mild Cognitive Impairment market report provides insights on the current and emerging therapies.
Mild Cognitive Impairment market report provides a global historical and forecasted market covering drug outreach in 7MM.
The Mild Cognitive Impairment market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Mild Cognitive Impairment market.

Got queries? Click here to know more about the Mild Cognitive Impairment Market Landscape https://www.delveinsight.com/sample-request/mild-cognitive-impairment-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Mild Cognitive Impairment Overview

Mild Cognitive Impairment (MCI) is an intermediate stage between normal cognitive aging and dementia, marked by a detectable decline in cognitive abilities that does not yet severely impact daily activities. Those affected may experience memory difficulties, reduced attention, and impaired judgment, increasing their risk of developing Alzheimer's disease or other forms of dementia.

With its rising prevalence, particularly among aging populations, early diagnosis and effective management strategies are becoming increasingly essential.

Mild Cognitive Impairment Market Outlook

Mild Cognitive Impairment (MCI) is characterized by cognitive decline that surpasses normal aging but does not severely affect daily life. Its potential progression to dementia, particularly Alzheimer's disease, highlights the need for early diagnosis and intervention. Management strategies prioritize addressing modifiable risk factors such as diet, hypertension, and physical activity. While pharmacological treatments like cholinesterase inhibitors (ChEIs) and memantine may be used in Alzheimer's-related cases, non-pharmacological approaches, including cognitive training, exercise, and lifestyle modifications, play a crucial role in managing MCI.

Due to the lack of a standardized treatment, personalized management is essential, particularly for individuals with comorbid conditions. Although ChEIs are commonly prescribed for Alzheimer's, their effectiveness in MCI remains uncertain, often leading to deprescribing recommendations. Drugs like donepezil, rivastigmine, and galantamine provide modest, temporary benefits, while memantine is more effective in moderate to severe cases.

As interest in advanced treatments grows, the MCI market is expanding, creating opportunities for innovation and investment in novel therapies and technologies. The market is expected to evolve with the potential introduction of therapies such as Valiltramiprosate, Mirodenafil, and Hydromethylthionine mesylate (HMTM). While these treatments could significantly influence market dynamics, their ultimate success remains uncertain.

Explore how the mild cognitive impairment market is rising in the upcoming years @ https://www.delveinsight.com/report-store/mild-cognitive-impairment-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Mild Cognitive Impairment Marketed Drugs
LEQEMBI (lecanemab): Biogen Inc./Eisai Co., Ltd.
KISUNLA (Donanemab): Eli Lilly and Company

Mild Cognitive Impairment Marketed Drugs

Valiltramiprosate (ALZ-801): Alzheon Inc.
Mirodenafil (AR1001): AriBio Co., Ltd.
Hydromethylthionine Mesylate (HMTM)/TRx0237: TauRx Therapeutics

Scope of the Mild Cognitive Impairment Market Report

Study Period: 2020-2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Mild Cognitive Impairment Companies: Alzheon Inc., AriBio Co., Ltd., Eli Lilly, Novo Nordisk, AgeneBio, Inc., Anavex Life Sciences Corp., TauRx Therapeutics, Araclon Biotech S.L., AC Immune SA, Johnson & Johnson, and others
Key Mild Cognitive Impairment Therapies: LEQEMBI (lecanemab), KISUNLA (Donanemab), and others
Mild Cognitive Impairment Therapeutic Assessment: Mild Cognitive Impairment current marketed and Mild Cognitive Impairment emerging therapies
Mild Cognitive Impairment Market Dynamics: Mild Cognitive Impairment market drivers and Mild Cognitive Impairment market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
Mild Cognitive Impairment Unmet Needs, KOL's views, Analyst's views, Mild Cognitive Impairment Market Access and Reimbursement

Download sample pages @ https://www.delveinsight.com/sample-request/mild-cognitive-impairment-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Table of Contents

1. Report Introduction
2. Executive Summary
3. SWOT analysis
4. Mild Cognitive Impairment Patient Share (%) Overview at a Glance
5. Mild Cognitive Impairment Market Overview at a Glance
6. Mild Cognitive Impairment Disease Background and Overview
7. Mild Cognitive Impairment Epidemiology and Patient Population
8. Country-Specific Patient Population of Mild Cognitive Impairment
9. Mild Cognitive Impairment Current Treatment and Medical Practices
10. Unmet Needs
11. Mild Cognitive Impairment Emerging Therapies
12. Mild Cognitive Impairment Market Outlook
13. Country-Wise Mild Cognitive Impairment Market Analysis (2020-2034)
14. Market Access and Reimbursement of Therapies
15. Market drivers
16. Market barriers
17. Appendix
18. Mild Cognitive Impairment Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Click here to read more about Mild Cognitive Impairment Market Outlook 2034 @ https://www.delveinsight.com/report-store/mild-cognitive-impairment-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Related Reports:

Mild Cognitive Impairment Pipeline Insights, DelveInsight

"Mild Cognitive Impairment Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Mild Cognitive Impairment market. A detailed picture of the Mild Cognitive Impairment pipeline landscape is provided, which includes the disease overview and Mild Cognitive Impairment treatment guidelines.

Contact Info:

Kritika Rehani, Team Leader Marketing & Branding
krehani@delveinsight.com
info@delveinsight.com
www.delveinsight.com
+14699457679

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.